Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma

The purpose of this study is to determine the efficacy and safety of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma.

Study Overview

• Status: Completed
• Conditions: Mantle Cell Lymphoma
• Intervention / Treatment: Drug: Bendamustine; Drug: Rituximab

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Ottawa, Canada
    • Teva Investigational Site 6
  • Toronto, Canada
    • Teva Investigational Site 7
• United States
  • California
    • Fountain Valley, California, United States
      • Teva Investigational Site 11
    • Los Angeles, California, United States
      • Teva Investigational Site 2
  • Florida
    • Orlando, Florida, United States
      • Teva Investigational Site 35
  • Indiana
    • Lafayette, Indiana, United States
      • Teva Investigational Site 30
  • Maryland
    • Bethesda, Maryland, United States
      • Teva Investigational Site 20
  • New Jersey
    • Hackensack, New Jersey, United States
      • Teva Investigational Site 4
  • New York
    • Buffalo, New York, United States
      • Teva Investigational Site 3
  • Pennsylvania
    • Gettysburg, Pennsylvania, United States
      • Teva Investigational Site 43
  • Texas
    • Bryan, Texas, United States
      • Teva Investigational Site 33
    • Grapevine, Texas, United States
      • Teva Investigational Site 41
  • Virginia
    • Lynchburg, Virginia, United States
      • Teva Investigational Site 23

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• histopathologically confirmed diagnosis of typical or atypical mantle cell lymphoma, except for blastoid type.
• documented relapsed/refractory mantle cell lymphoma.
• CD20 positive B cells in the lymph node biopsy or other lymphoma pathology specimen.
• adequate hematologic function according to specific trial parameters.
• bidimensionally measurable disease with at least 1 lesion measuring 2.0 cm or more in a single dimension, or the patient is in the leukemic phase of the disease.
• patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• patient has an estimated life expectancy of at least 3 months.
• women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study.
• men not surgically sterile or who are capable of producing offspring must practice abstinence or use a barrier method of birth control, and must agree to continue use of this method for the duration of study drug treatment and for 30 days after participation in the treatment period.

Exclusion Criteria:

• has received more than 3 previous standard chemotherapy regimens.
• has the blastoid subtype of mantle cell lymphoma.
• documented history of central nervous system (CNS) lymphomatous involvement.
• a history of previous high-dose chemotherapy with allogeneic stem cell transplantation (history of autologous stem cell transplantation is allowed).
• previous treatment with bendamustine.
• has an active malignancy other than MCL, or has had a malignancy other than MCL within the past 3 years, except for controlled prostate cancer without evidence of bone metastases, localized bladder cancer, cervical carcinoma in situ, breast cancer in situ, or non-melanoma skin cancer.
• has New York Heart Association (NYHA) Class III or IV heart failure, arrhythmias or unstable angina, electrocardiographic evidence of active ischemia or active conduction system abnormalities, or myocardial infarction within the last 6 months.
• has serum creatinine of more than 2.0 mg/dL or creatinine clearance of less than 30 mL/min based on the Cockcroft-Gault method or from a 24-hour urine collection.
• does not have adequate hepatic organ function as evidenced by specific trial parameters.
• has known human immunodeficiency virus (HIV) infection.
• has active hepatitis B infection. Hepatitis B surface antigen must be tested.
• a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
• has received corticosteroids within 28 days of study entry unless chronically administered (prednisone ≤20 mg/day) for indications other than lymphoma or lymphoma-related complications.
• any serious uncontrolled, medical or psychological disorder that would impair the ability of the patient to participate in or complete this study.
• any condition which places the patient at unacceptable risk or confounds the ability of the investigators to interpret study data.
• patient has received other investigational agent(s) within 28 days of study entry.
• patient has received chemotherapy within the prior 28 days.
• patient has a known hypersensitivity to bendamustine, mannitol, or rituximab.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Bendamustine+Rituximab; Patients receive bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2, and 375 mg/m^2 of rituximab by iv on day 1 of each 28-day cycle. Six 28-day cycles were planned and up to 8 cycles permitted for patients who do not have progressive disease and who have not achieved a complete response (CR).

Drug: Bendamustine; Bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.; Other Names: bendamustine HCl; TREANDA®; CEP-18083; Drug: Rituximab; Patients receive 375 mg/m^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.; Other Names: Rituxan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (Complete Response + Partial Response) at the End of Cycles 3 and 6 Using the 2007 International Working Group Criteria	The International Working Group (IWG) criteria (Cheson et al 2007) for a complete response is a complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. A partial response is at least a 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase should be observed in the size of other nodes, liver or spleen, and no new sites of disease should be observed. 95% CIs are calculated using binomial exact method.	Month 3 (end of cycle 3), Month 6 (end of cycle 6)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Kaplan-Meier Estimate for Duration of Response	Duration of response is defined as the time between the date of the first response to date of progression or death. Response is determined on the basis of the 2007 IWG criteria. A complete response is a complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. A partial response is at least a 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase should be observed in the size of other nodes, liver or spleen, and no new sites of disease should be observed.	Day 1 up to Month 43
Kaplan-Meier Estimate for Progression-Free Survival	Progression-free survival is defined as the time from first exposure to study medication to disease progression or relapse, or death due to any cause. Progression is defined using the 2007 International Working Group criteria, as any new lesion or increase by at least 50% of previously involved sites from nadir.	Day 1 up to Month 45
Kaplan-Meier Estimate for Overall Survival	Overall survival is defined as the time from first exposure to study medication to death, or to last date from adverse events, concomitant medications, vital signs, lost to follow-up, or last known alive, for overall survival censoring date.	Day 1 up to Month 57
Shifts in Baseline to Post-Treatment in Positron Emission Tomography (PET)	Participants had a whole-body PET at baseline and at the end of cycle 6 or the end-of-treatment visit. Negative PET refers to PET results showing no abnormal lymph nodes; conversely, positive PET refers to PET results showing abnormal lymph nodes.	Baseline (Days -30 to 0), post treatment (up to Month 9, 30 days following completion of therapy)
Shifts in Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status	The ECOG scale is: Grade 0: Fully active, able to carry on all pre-disease activities without restriction;; Grade 1: Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature;; Grade 2: Ambulatory and capable of all self-care but unable to work. Up and about more than 50% of waking hours;; Grade 3: Capable of only limited self-care, confined to bed or chair > 50% of waking hours;; Grade 4: Completely disabled. Cannot carry on any self-care. Confined to bed or Chair. The shift table compares baseline ECOG scores to the ECOG scores as of the last treatment visit.	Day 0 (baseline) up to Month 8

Collaborators and Investigators

• Sponsor: Cephalon

Study record dates

Study Major Dates

• Study Start: June 1, 2009
• Primary Completion (Actual): December 1, 2011
• Study Completion (Actual): May 1, 2014

Study Registration Dates

• First Submitted: April 29, 2009
• First Submitted That Met QC Criteria: April 29, 2009
• First Posted (Estimate): May 1, 2009

Study Record Updates

• Last Update Posted (Estimate): November 4, 2014
• Last Update Submitted That Met QC Criteria: October 28, 2014
• Last Verified: October 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, Mantle-Cell; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Rituximab
• Other Study ID Numbers: C18083/2039/NL/US-CA

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No